Sentences with phrase «regulatory acts which»

regulatory acts which are of direct concern to them and does not entail implementing measures (new under Lisbon Treaty)

(ii) against certain acts of general application, namely regulatory acts which are of direct concern to them and do not entail implementing measures.

Any natural or legal person may, under the conditions laid down in the first and second paragraphs, institute proceedings against an act addressed to that person or which is of direct and individual concern to them, and against a regulatory act which is of direct concern to them and does not entail implementing measures.

Thus the new article adds that any natural or legal person can also challenge «a regulatory act which is of direct concern to them and does not entail implementing measures.»

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

You see that Orphan Drug Act (and a confluence of other factors as well, both regulatory and economic) helped set the stage for the Wild West marketplace we have now, in which gun - slinging drug makers can charge into town and charge whatever the heck they want for their wares.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Among the grab bag of goodies in the pharma - backed 21st Century Cures Act, which is meant to hasten FDA drug approvals, is a provision that would essentially remove the agency from the mobile health app and electronic medical records regulatory process.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Title II of the Jumpstart Our Business Startups Act (JOBS Act), which went into effect today, has lifted the ban on «general solicitation» of investments by companies that rely on a widely used regulatory exemption to issue securities.

In 2017, the top 10 regulatory interventions included ensuring alcohol ads are targeted responsibly online — especially on social media platforms where many users are under 18, which landed Diageo in trouble in 2016; acting against irresponsible gambling advertising; new food advertising restrictions for products which are high in fat, salt or sugar (HFSS); and addressing harmful gender stereotypes, for which a detailed report is due in the coming weeks.

WASHINGTON, D.C. — U.S. Chamber President and CEO Thomas J. Donohue issued the following statement today in response to U.S. Senate passage of S. 2155, the «Economic Growth, Regulatory Relief, and Consumer Protection Act,» which will alleviate regulatory burdens for America's local and community banks:

Actual results may vary materially from those expressed or implied by forward - looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval of the Merger Agreement, (c) the parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act, (d) other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied, (e) all or part of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee of $ 74 million, or (c) the circumstances of the termination, including the possible imposition of a 12 - month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency of the Merger may have on BWW and its business, including the risks that as a result (a) BWW's business, operating results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal, regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016, as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

Unconscionable conduct (agrees with NFF that they have not provided protection and support reforms «to provide transparency in the supply chain» and recognise that «certain classes of suppliers... are predisposed to suffering from a special disadvantage...»; misuse of market power (legal framework must «level the balance of market power in negotiations...», «ensure transparency in the transmission of market prices» and «not allow for final market risks to be borne by the primary producer» and provide «transparency of contract processes» - specifically, Canegrowers supports effects test and a process giving ACCC greater power to «regulate anti-competitive behaviour and impose penalties», shifting «the decisions framework from the judicial system to a regulatory system» which would make it more accessible to small producers); collective bargaining (notes limits of Sugar Industry Act (Qld); authorisation and notification approval costly and limited and not a viable alternative - peak bodies should be able to «commence and progress collective bargaining with mills on behalf of their members» and current threshold too restrictive)» competitive neutrality (mixed outcomes - perverse outcomes in the case of natural monopolies - suggest remove «application of competitive neutrality provisions to natural monopoly essential services»)

Marking the first anniversary of the Government's moratorium from new domestic regulation for micro businesses, the FSB has published a report which argues that the Regulatory Policy Committee (RPC) needs more powers to scrutinise performance, advocate regulatory reform and act as an ombudsman.

This is because the Supreme Court has ruled that, when a grant of regulatory authority «lay [s] down by legislative act an intelligible principle to which the person or body authorized to [act] is directed to conform», Congress is not unconstitutionally delegating its ability to make laws.

Her lab also discovered a hidden regulatory landscape on the surfaces of cellular proteins, which act as traffic cops for telomerase.

The goal of ENCODE is to build a comprehensive parts list of functional elements in the human genome, including elements that act at the protein and RNA levels, and regulatory elements that control cells and circumstances in which a gene is active.

Unfortunately, the FDA, which regulates cosmetics under the Federal Food, Drug, and Cosmetic Act, has not defined the term «natural» and has not established a regulatory definition for this term in cosmetic labeling.

And there are also a number of federal laws that relate to student privacy, one of which is the 40 - year - old Family Educational Rights and Privacy Act (FERPA), which has undergone regulatory changes in recent years that some claimed have weakened it.

(Sec. 9207) The bill amends the Education Flexibility Partnership Act of 1999 to make several changes to the Educational Flexibility Program, through which ED may authorize an SEA to waive certain statutory or regulatory program requirements established under either the ESEA or the Carl D. Perkins Career and Technical Education Act of 2006.

The Education Department's Office for Civil Rights (OCR), which developed the letter, contends that Title VI of the 1964 Civil Rights Act authorized this far - reaching regulatory action.

The bill, known as the Promoting Real Opportunity, Success, and Prosperity through Education Reform (PROSPER) Act, would also make more money and regulatory flexibility available to for - profit colleges, many of which have been cited for high costs, low graduation rates and a history of taking advantage of low - income students and military veterans.

The timing and extent to which the rate increases might be granted can vary by the applicable regulatory agency, and the outcome of these filings are expected to consider the effects of the recently enacted Tax Cuts and Jobs Act.»

I invite each interested SEA to request this flexibility pursuant to the authority in section 9401 of the Elementary and Secondary Education Act of 1965 (ESEA), which allows me to waive, with certain exceptions, any statutory or regulatory requirement of the ESEA for an SEA that receives funds under a program authorized by the ESEA and requests a waiver.

One regulatory change that actually helped brokers was the Secure and Fair Enforcement for Mortgage Licensing Act, which requires all loan officers to register with the Nationwide Multistate Licensing System and undergo background checks.

If regulatory reform makes nominating directors a simpler and cheaper process — which the SEC's proposed «proxy access» rules do — then the «tools of Internet and social networking» become potent weapons that act to level the playing field for the smaller investor.

a. The licensee, by itself or with its affiliates, is licensed in five or more states to engage in the mortgage lending business and (i) is supervised by a state or federal regulatory agency whose regulatory scheme has been determined by the Commissioner to be substantially similar to that of North Carolina, (ii) is organized and supervised under the laws of a state that has adopted a model licensing law endorsed by the Commissioner; or (iii) is supervised by a state or federal agency that is a party to an interstate compact, or has otherwise entered into a cooperative reciprocal agreement by which the state or federal regulatory agency and the State of North Carolina, directly or by duly authorized act of the Commissioner, have mutually agreed to recognize state licensing laws which have specific enumerated criteria.

The authors of the study point to other regulatory and legislative acts, including the «order precedence rule,» commonly known as the «Manning Rule» after a legal case against Charles Schwab, the Gramm - Leach - Bliley Act, which saw the end of the Glass - Steagall Act of 1933 and formally allowed the combination of commercial banks, securities firms and insurance companies, Regulation Fair Disclosure, which devalued stock research, and the Global Settlement ruling, which has made research coverage tougher for issuers to secure.

Since 2013, the subcommittee has orchestrated several successes and positive outcomes, some of which include: • Collaborating with the PIJAC Zoonosis committee to update the Healthy Herp Handling poster promoting healthy reptile and amphibian handling practices; develop the Zoonotic Disease Prevention Series for Retailers; draft informative store signage on how to prevent zoonotic diseases; participate in meetings on rodent and reptile disease transmission with the Centers for Disease Control; and produce and revise best management practices (BMP) documents; • Collaborating with the United States Association of Reptile Keepers on past and current attempts to pass legislation, ordinances, and regulatory activity that may impact herp ownership and related businesses; • Attending Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) meetings with reports and summary of actions affecting import and export of reptiles; • Addressing the 2013 Center for Biological Diversity petition to list 53 herp species under the Endangered Species Act; • Reviewing and commenting on the recent US Fish and Wildlife status review on the proposal to list wood turtles under the Endangered Species Act; • Submitting comments on proposed listing of flat - tailed tortoise and spider tortoise under the Endangered Species Act; • Introducing federal legislation in 2013 to allow for the export of certain constrictors listed as injurious in air shipments with aircraft that land in a state for refueling; • Providing volunteer support for auctions at 2013 National Reptile Breeders Expo and several North American Reptile Breeders Conferences; • Providing extensive consultation on constrictor caging standards in Ohio.

We banned cockfighting, made dogfighting a felony offense, passed licensing and regulatory control of puppy mills, increased penalties for neglect and abuse, covered birds under cruelty statutes, regulated the keeping of large carnivores, preserved local regulations on farm animals, and most recently, we helped pass the Canine Cruelty Prevention Act which has closed down over 1,200 puppy mills.

The gene product's precise role is not currently understood but it is thought to anchor regulatory complexes at the photoreceptor connecting cilium, which acts as a bridge between the inner and outer segments of photoreceptor cells [43] as well as having functions in disk morphogenesis [42] and in the structure of the ciliary axoneme [44].

The Entertainment Software Ratings Board (ESRB), which assigns content ratings to video games sold in the US and acts as an independent self - regulatory body for the industry, told Kotaku it «does not consider loot boxes to be gambling.»

As I remarked to Rud and to David, now that the endangerment finding for carbon pollution has been published and has been successfully defended in the courts, the EPA is assigned by law to act as the central coordinating agency of government in crafting a regulatory pathway which mitigates the dangers of carbon pollution, as those dangers are described in the finding.

-- Notwithstanding any other provision of this Act or the Federal Power Act, a State legislature or regulatory authority may set the rates for a sale of electric energy by a facility generating electric energy from renewable energy sources pursuant to a State - approved production incentive program under which the facility voluntarily sells electric energy.

Justice Ruth Bader Ginsberg in the court opinion wrote, «Maryland's regulatory program to encourage development of new in - state energy generation is preempted by the Federal Power Act, which vests in the Federal Energy Regulatory Commission exclusive jurisdiction over interstate wholesale electricity rates.»

Long time ago economic regulatory admin, issued Natural gas policy act (1978) and PURPA which forbade natural gas use in power plants.

Assuming that Congress continues to do nothing on climate, that $ 655 billion floor for regulatory justification (and the totally unknown ceiling) will prove significant when at some point a hypothetical second Clinton Administration — which promises to be serious about climate in a way that the Obama Administration apparently has not been — resorts to Section 115 of the Clean Air Act to regulate greenhouse gas emissions.

From its conception, the Clean Power Plan (which became the global warming regulatory bit of the Clean Air Act) has been controversial due to its aggressiveness in (supposedly) reducing greenhouse gases.

In December 1918, Parliament passed a bill to establish a Commission with both regulatory and investigative powers, including taking over the enforcement of the existing Electric Light and Power Act, which regulated all electricity generators and distributors.

«The administration is engaged with Congress to pass cap - and - trade legislation, which the president believes is far superior to a regulatory approach using the existing Clean Air Act.»

The American Enterprise Institute (AEI) estimates that all of this unnecessary regulatory pain asserted under authority of the 1970 Clean Air Act which Congress never intended for «climate pollution» will reduce temperatures only about 0.0015 of one degree by the year 2100.

While she notes that the «purpose of the revision of the former fourth paragraph of Article 230 EC by the present fourth paragraph of Article 263 TFEU was undoubtedly to strengthen individual legal protection by extending the legal remedies available to natural and legal persons against European Union acts of general application» (para. 33), she nevertheless continues by making three arguments which underline the General Court's interpretation of what regulatory acts entail.

The Standards Council of Canada Act, and the Council's regulatory texts establish a process of «voluntary standardization,» which must be: (a) independent of government; (b) serve the public interest; and, (c) achieve a consensus of all parties concerned, which makes necessary a large committee.

This has lead the drafters of the Treaties to change the wording of article 263 TFEU which now no longer requires individual applicants to be individually concerned when challenging «regulatory acts».

the expression «regulatory act» is difficult to reconcile with the mandate of the 2007 Intergovernmental Conference which negotiated the Treaty of Lisbon.

I am not aware of any subsequent statutory, regulatory or case law developments in India which have changed this situation, but that kind of tweak of IT Act regulations in India wouldn't necessary make headlines outside of the local IT industry press coverage in obscure trade journals.

These efforts include those of former Firm Partner and State Assemblyman John T. Knox, co-author of the Knox - Keene Health Care Service Plan Act of 1975 and the Moscone - Knox Professional Corporation Act and current Partner Richard Spohn, who was and remains outside counsel and collaborator in the conceptualization, regulatory approval and implementation of the first private sector healthcare services exchange, the CaliforniaChoice program, which is today the oldest and largest of such structures.

This is also confirmed by the preparatory documents of the European Convention on Article III ‑ 270 (4) of the Draft Treaty establishing a Constitution for Europe, (23) the provision which subsequently reappeared in the Constitutional Treaty as Article III - 365 (4); according to those documents, the wording «acts of general application» was debated in the Convention, but ultimately rejected and replaced by the more restrictive expression «regulatory act», which was intended to express the distinction between legislative and non-legislative acts.